ZA200405342B - The use of melagatran for the manufacture of a medicament for the treatment of type i diabetes mellitus - Google Patents

The use of melagatran for the manufacture of a medicament for the treatment of type i diabetes mellitus

Info

Publication number
ZA200405342B
ZA200405342B ZA2004/05342A ZA200405342A ZA200405342B ZA 200405342 B ZA200405342 B ZA 200405342B ZA 2004/05342 A ZA2004/05342 A ZA 2004/05342A ZA 200405342 A ZA200405342 A ZA 200405342A ZA 200405342 B ZA200405342 B ZA 200405342B
Authority
ZA
South Africa
Prior art keywords
melagatran
medicament
manufacture
treatment
type
Prior art date
Application number
ZA2004/05342A
Other languages
English (en)
Inventor
Korsgren Olle
Nilsson Bo
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ZA200405342B publication Critical patent/ZA200405342B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2004/05342A 2002-01-23 2004-07-05 The use of melagatran for the manufacture of a medicament for the treatment of type i diabetes mellitus ZA200405342B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0200198A SE0200198D0 (sv) 2002-01-23 2002-01-23 New use
PCT/SE2003/000087 WO2003061682A1 (en) 2002-01-23 2003-01-21 The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus

Publications (1)

Publication Number Publication Date
ZA200405342B true ZA200405342B (en) 2005-09-28

Family

ID=20286751

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2004/05342A ZA200405342B (en) 2002-01-23 2004-07-05 The use of melagatran for the manufacture of a medicament for the treatment of type i diabetes mellitus

Country Status (14)

Country Link
US (2) US7045502B2 (https=)
EP (1) EP1469874A1 (https=)
JP (1) JP2005516035A (https=)
KR (1) KR20040075096A (https=)
CN (1) CN100430089C (https=)
BR (1) BR0306798A (https=)
CA (1) CA2472241A1 (https=)
IL (1) IL162853A0 (https=)
MX (1) MXPA04007192A (https=)
NO (1) NO20043483L (https=)
NZ (1) NZ533749A (https=)
SE (1) SE0200198D0 (https=)
WO (1) WO2003061682A1 (https=)
ZA (1) ZA200405342B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0200198D0 (sv) * 2002-01-23 2002-01-23 Astrazeneca Ab New use
JP6155187B2 (ja) 2010-03-30 2017-06-28 ヴァーセオン コーポレイション トロンビンの阻害剤としての多置換芳香族化合物
HK1214252A1 (zh) 2013-03-15 2016-07-22 Verseon Corporation 作為凝血酶抑制劑的鹵代吡唑
CN110179795A (zh) 2013-03-15 2019-08-30 维颂公司 作为丝氨酸蛋白酶抑制剂的多取代芳族化合物的制药用途
US10189810B2 (en) 2014-09-17 2019-01-29 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
CN107405333A (zh) 2015-02-27 2017-11-28 维颂公司 作为丝氨酸蛋白酶抑制剂的被取代的吡唑化合物
CN113164765B (zh) 2018-07-13 2026-03-20 维颂国际公司 凝血酶抑制剂、制剂及其用途
JP2024535677A (ja) 2021-08-11 2024-10-02 サナ バイオテクノロジー，インコーポレイテッド 即時血液媒介性炎症反応を減少させるための同種細胞療法を目的とした遺伝子改変細胞
KR20240155390A (ko) 2022-02-17 2024-10-28 사나 바이오테크놀로지, 인크. 조작된 cd47 단백질 및 이의 용도
WO2024229302A1 (en) 2023-05-03 2024-11-07 Sana Biotechnology, Inc. Methods of dosing and administration of engineered islet cells
CN121604968A (zh) 2023-05-22 2026-03-03 萨那生物科技公司 递送胰岛细胞的方法及相关方法
AU2024328949A1 (en) 2023-08-23 2026-03-12 Sana Biotechnology, Inc. Modified cd47 proteins and their uses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301916D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
TWI238827B (en) 1995-12-21 2005-09-01 Astrazeneca Ab Prodrugs of thrombin inhibitors
SE9900070D0 (sv) * 1999-01-13 1999-01-13 Astra Ab New use
SE523817C2 (sv) 1999-02-05 2004-05-18 Corline Systems Ab Användning av ett koagulationsförebyggande ämne i samband med transplantation av insulinproducerande celler
US6462021B1 (en) 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
SE0200198D0 (sv) * 2002-01-23 2002-01-23 Astrazeneca Ab New use

Also Published As

Publication number Publication date
CA2472241A1 (en) 2003-07-31
US7045502B2 (en) 2006-05-16
EP1469874A1 (en) 2004-10-27
IL162853A0 (en) 2005-11-20
US20050090424A1 (en) 2005-04-28
WO2003061682A1 (en) 2003-07-31
NZ533749A (en) 2006-02-24
SE0200198D0 (sv) 2002-01-23
CN100430089C (zh) 2008-11-05
BR0306798A (pt) 2004-12-07
KR20040075096A (ko) 2004-08-26
NO20043483L (no) 2004-08-20
JP2005516035A (ja) 2005-06-02
US20060148720A1 (en) 2006-07-06
CN1729010A (zh) 2006-02-01
MXPA04007192A (es) 2004-10-29

Similar Documents

Publication Publication Date Title
PL370818A1 (en) Dosage form for treatment of diabetes mellitus
MXPA03006936A (es) Tratamiento de diabetes mellitus.
AU2003234529A8 (en) Glp-1 gene delivery for the treatment of type 2 diabetes
IL176259A (en) Use of cystamine in combination with metformin to prepare a cure for diabetes or related complications
IL213806A0 (en) Use of derivatives of n-phenylpiperazin-1-yl-acetamide for the preparation of a pharmaceutical compositions for treatment of diabetes related conditions
IL218909A0 (en) Treatment of diabetes
EG24124A (en) Pharmaceutical compositions for the treatment of type-II diabetes mellitus
AU2003279338A1 (en) Phenethanolamine derivatives for the treatment of respiratory diseases
AU2003234929A1 (en) Therapeutic agent for diabetes
TWI345975B (en) Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
AU2003279442A8 (en) 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
PL377164A1 (pl) Pochodne anilinopirazolu przydatne do leczenia cukrzycy
ZA200405342B (en) The use of melagatran for the manufacture of a medicament for the treatment of type i diabetes mellitus
AU2003203146A1 (en) Use of glp-1 compound for treatment of critically ill patients
IL165242A0 (en) Treatment for diabetes
AU2003252182A1 (en) Therapeutic treatment for the metabolic syndrome and type 2 diabetes
AU2003296545A1 (en) Use of a trpm8-activating substance for the treatment of tumours
AUPS286302A0 (en) Medication inhaler
AU2003209542A8 (en) Use of s-substituted l-crysteine for the manufacture of a medicament for the treatment of dermatological disorders
HK1069107A (en) The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus
GB0212790D0 (en) Medicament for the treatment of diabetes
AU2002311141A1 (en) The use of hydrochloric acid in the preparation of a medicament for the treatment of tumour
ZA200409489B (en) Treatment for diabetes.
WO2003075946A3 (en) Treatment of type i diabetes mellitus using growth hormone antagonist
WO2004082591A8 (en) Pharmaceutical composition for treatment of diabetes mellitus